Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:51 UTC |
---|
Update Date | 2022-03-07 02:51:51 UTC |
---|
HMDB ID | HMDB0015088 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Rizatriptan |
---|
Description | Rizatriptan is only found in individuals that have used or taken this drug. It is a triptan drug used for the treatment of migraine headaches. It is a selective 5-hydroxytryptamine1 receptor subtype agonist.Three distinct pharmacological actions have been implicated in the antimigraine effect of the triptans: (1) stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation; (2) direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem and (3) vasoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism. |
---|
Structure | CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2 InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3 |
---|
Synonyms | Value | Source |
---|
MK 462 Free base | ChEBI | N,N-Dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]-ethanamine | ChEBI | N,N-Dimethyl-5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indole-3-ethanamine | ChEBI | Risatriptan | ChEBI | Rizatriptanum | ChEBI | Maxalt | Kegg | Rizatriptan benzoat | HMDB | Rizatriptan benzoate | HMDB | N,N-Dimethyl-2-(5-(1,2,4-triazol-1-ylmethyl)-1H-indole-3-yl)ethylamine | HMDB |
|
---|
Chemical Formula | C15H19N5 |
---|
Average Molecular Weight | 269.3449 |
---|
Monoisotopic Molecular Weight | 269.164045633 |
---|
IUPAC Name | dimethyl({2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethyl})amine |
---|
Traditional Name | maxalt |
---|
CAS Registry Number | 145202-66-0 |
---|
SMILES | CN(C)CCC1=CNC2=C1C=C(CN1C=NC=N1)C=C2 |
---|
InChI Identifier | InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3 |
---|
InChI Key | ULFRLSNUDGIQQP-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as tryptamines and derivatives. Tryptamines and derivatives are compounds containing the tryptamine backbone, which is structurally characterized by an indole ring substituted at the 3-position by an ethanamine. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Indoles and derivatives |
---|
Sub Class | Tryptamines and derivatives |
---|
Direct Parent | Tryptamines and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Tryptamine
- 3-alkylindole
- Indole
- Aralkylamine
- Substituted pyrrole
- Benzenoid
- Azole
- Pyrrole
- 1,2,4-triazole
- Heteroaromatic compound
- Tertiary aliphatic amine
- Tertiary amine
- Azacycle
- Organopnictogen compound
- Organonitrogen compound
- Amine
- Hydrocarbon derivative
- Organic nitrogen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Not Available | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 178 - 180 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.34 g/L | Not Available | LogP | 1.4 | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Rizatriptan,1TMS,isomer #1 | CN(C)CCC1=CN([Si](C)(C)C)C2=CC=C(CN3C=NC=N3)C=C12 | 2562.1 | Semi standard non polar | 33892256 | Rizatriptan,1TMS,isomer #1 | CN(C)CCC1=CN([Si](C)(C)C)C2=CC=C(CN3C=NC=N3)C=C12 | 2745.8 | Standard non polar | 33892256 | Rizatriptan,1TMS,isomer #1 | CN(C)CCC1=CN([Si](C)(C)C)C2=CC=C(CN3C=NC=N3)C=C12 | 3326.5 | Standard polar | 33892256 | Rizatriptan,1TBDMS,isomer #1 | CN(C)CCC1=CN([Si](C)(C)C(C)(C)C)C2=CC=C(CN3C=NC=N3)C=C12 | 2764.2 | Semi standard non polar | 33892256 | Rizatriptan,1TBDMS,isomer #1 | CN(C)CCC1=CN([Si](C)(C)C(C)(C)C)C2=CC=C(CN3C=NC=N3)C=C12 | 2924.5 | Standard non polar | 33892256 | Rizatriptan,1TBDMS,isomer #1 | CN(C)CCC1=CN([Si](C)(C)C(C)(C)C)C2=CC=C(CN3C=NC=N3)C=C12 | 3400.0 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Rizatriptan GC-MS (Non-derivatized) - 70eV, Positive | splash10-0a4i-9130000000-5d4f05bf987cb9fd7f28 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Rizatriptan GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Rizatriptan LC-ESI-qTof , Positive-QTOF | splash10-0udi-0590000000-de0b61f549c5a86c98df | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Rizatriptan , positive-QTOF | splash10-0udi-0590000000-de0b61f549c5a86c98df | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Rizatriptan 35V, Negative-QTOF | splash10-014i-9000000000-2ee19b9378ec57dc6f43 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Rizatriptan 35V, Positive-QTOF | splash10-0a4i-3940000000-fea36e233d8f7992136d | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rizatriptan 10V, Positive-QTOF | splash10-00di-0090000000-ec16b67adaf4329a82c3 | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rizatriptan 20V, Positive-QTOF | splash10-0fb9-0390000000-142ab3615bb7e088f890 | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rizatriptan 40V, Positive-QTOF | splash10-05fr-5920000000-27bd73d39b069bbb2232 | 2016-08-02 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rizatriptan 10V, Negative-QTOF | splash10-014i-9070000000-08285abbdf6e069d2775 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rizatriptan 20V, Negative-QTOF | splash10-014i-9060000000-4bb5daacabdae76b4c33 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rizatriptan 40V, Negative-QTOF | splash10-00kf-9000000000-308c89a78f967378d554 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rizatriptan 10V, Positive-QTOF | splash10-0uk9-0290000000-c3ca4cb34ec759f725f9 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rizatriptan 20V, Positive-QTOF | splash10-004i-1190000000-6aedfe651c028f506d3d | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rizatriptan 40V, Positive-QTOF | splash10-00di-9300000000-0f35fc5e2bd4d164a051 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rizatriptan 10V, Negative-QTOF | splash10-014i-7090000000-43c2efadf3b9b7e5b6dd | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rizatriptan 20V, Negative-QTOF | splash10-014i-9010000000-a3f5fa7f89b227f2c0a3 | 2021-10-11 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Rizatriptan 40V, Negative-QTOF | splash10-014i-9200000000-74919258163afaab3251 | 2021-10-11 | Wishart Lab | View Spectrum |
|
---|
General References | - Tfelt-Hansen P, De Vries P, Saxena PR: Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000 Dec;60(6):1259-87. [PubMed:11152011 ]
- Villalon CM, Centurion D, Valdivia LF, De Vries P, Saxena PR: An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210. [PubMed:12434581 ]
- Wellington K, Plosker GL: Rizatriptan: an update of its use in the management of migraine. Drugs. 2002;62(10):1539-74. [PubMed:12093318 ]
- Wellington K, Jarvis B: Spotlight on rizatriptan in migraine. CNS Drugs. 2002;16(10):715-20. [PubMed:12269863 ]
- Ikemoto F, Toru T, Aijima H, Natsumeda Y: [Rizatriptan (Maxalt), a new entity of triptan for migraine: pharmacology and therapeutic relevance]. Nihon Yakurigaku Zasshi. 2004 Apr;123(4):295-302. [PubMed:15056946 ]
|
---|